BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Roca TP, Villar LM, Nogueira Lima FS, Vasconcelos MPA, Borzacov LMP, Silva EDCE, Lago BVD, Silva MTLD, Botelho Souza LF, Salcedo JMV, Santos ADOD, Vieira DS. Genomic Variability of Hepatitis B Virus Circulating in Brazilian Western Amazon. Viruses 2022;14:2100. [DOI: 10.3390/v14102100] [Reference Citation Analysis]
2 de Almeida Ribeiro CR, Martinelli KG, da Motta de Mello V, Spitz N, Araújo ORC, Lewis-ximenez LL, Araujo NM, de Paula VS. Association of Pre-S/S and Polymerase Mutations with Acute and Chronic Hepatitis B Virus Infections in Patients from Rio de Janeiro, Brazil. Viruses 2022;14:1375. [DOI: 10.3390/v14071375] [Reference Citation Analysis]
3 Liu T, Sun Q, Gu J, Cen S, Zhang Q. Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to D. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105348] [Reference Citation Analysis]
4 Bezerra CS, Portilho MM, Barbosa JR, de Azevedo CP, Mendonça ACDF, da Cruz JNM, Frota CC, do Lago BV, Villar LM. Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-05264-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang Y, Xiao X, Chen S, Huang C, Zhou J, Dai E, Li Y, Liu L, Huang X, Gao Z, Wu C, Fang M, Gao C. The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing. Front Immunol 2021;12:775461. [PMID: 34899733 DOI: 10.3389/fimmu.2021.775461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
7 Jeong H, Kim DH, Choi YM, Choi H, Kim D, Kim BJ. rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome. Microorganisms 2021;9:601. [PMID: 33803998 DOI: 10.3390/microorganisms9030601] [Reference Citation Analysis]
8 Lee AR, Cho JY, Kim JC, Dezhbord M, Choo SY, Ahn CH, Kim NY, Shin JJ, Park S, Park ES, Won J, Kim DS, Lee JH, Kim KH. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. Int J Mol Sci 2021;22:1606. [PMID: 33562603 DOI: 10.3390/ijms22041606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Yim HJ, Suh SJ, Jung YK, Hwang SG, Seo YS, Um SH, Lee SH, Kim YS, Jang JY, Kim IH, Kim HS, Kim JH, Lee YS, Yoon EL, Song MJ, Park JY. Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. J Viral Hepat 2020;27:1306-18. [PMID: 32706461 DOI: 10.1111/jvh.13363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Mokaya J, McNaughton AL, Bester PA, Goedhals D, Barnes E, Marsden BD, Matthews PC. Hepatitis B virus resistance to tenofovir: fact or fiction? Wellcome Open Res. 2020;5:151. [PMID: 33869791 DOI: 10.12688/wellcomeopenres.15992.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ye H, Teng J, Lin Z, Wang Y, Fu X. Analysis of HBsAg mutations in the 25 years after the implementation of the hepatitis B vaccination plan in China. Virus Genes 2020;56:546-56. [PMID: 32542478 DOI: 10.1007/s11262-020-01773-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Jiang D, Zeng H, Wang X. Response to comments on: Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int 2020;40:730. [PMID: 31811784 DOI: 10.1111/liv.14319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Liang B, Zheng X. Comments on 'Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance'. Liver Int 2020;40:729. [PMID: 31705783 DOI: 10.1111/liv.14290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Jiang D, Wang J, Zhao X, Li Y, Zhang Q, Song C, Zeng H, Wang X. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance. Liver Int 2020;40:83-91. [PMID: 31498528 DOI: 10.1111/liv.14241] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
17 Luo D, Liu Y, Chen R, Niu M, Liu L, Li X, Li Q, Huang B, Wang J, Xu D, Lin S. Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment. Antiviral Res. 2019;170:104579. [PMID: 31398372 DOI: 10.1016/j.antiviral.2019.104579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Liu Y, Zhou Y, Li X, Niu M, Chen R, Shao J, Si L, Luo D, Lin Y, Li L, Zhang K, Xiao X, Xu Z, Liu M, Lu M, Zoulim F, Xu D. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. Emerg Microbes Infect. 2019;8:354-365. [PMID: 30866789 DOI: 10.1080/22221751.2019.1584018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, Ying R, Guan Y, Li F. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:77-84. [PMID: 31380586 DOI: 10.1111/jvh.13165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Xiang K, Xiao Y, Li Y, He L, Wang L, Zhuang H, Li T. The Effect of the Hepatitis B Virus Surface Protein Truncated sC69 Mutation on Viral Infectivity and the Host Innate Immune Response. Front Microbiol 2019;10:1341. [PMID: 31249567 DOI: 10.3389/fmicb.2019.01341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, Pinedo-Villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 2019;19:829. [PMID: 31242901 DOI: 10.1186/s12889-019-7095-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
22 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
23 Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019;70:1093-102. [PMID: 30794889 DOI: 10.1016/j.jhep.2019.02.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 22.8] [Reference Citation Analysis]
24 Li S, Li S, Wu S, Chen L. Exosomes Modulate the Viral Replication and Host Immune Responses in HBV Infection. Biomed Res Int 2019;2019:2103943. [PMID: 31275965 DOI: 10.1155/2019/2103943] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
25 Jiang D, Wang J, Zhao X, Li Y, Zhang Q, Song C, Zeng H, Wang X. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.. [DOI: 10.1101/632984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Jia J, Li Y, Wei C, Guo R, Xu H, Jia Y, Wu Y, Li Y, Wei Z, Qi X, Li Z, Gao X. Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection. Exp Ther Med 2019;17:4730-40. [PMID: 31086607 DOI: 10.3892/etm.2019.7482] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Huang SW, Hung SJ, Wang JR. Application of deep sequencing methods for inferring viral population diversity. J Virol Methods 2019;266:95-102. [PMID: 30690049 DOI: 10.1016/j.jviromet.2019.01.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 18.8] [Reference Citation Analysis]
29 Mokaya J, Burn E, Tamandjou CR, Goedhals D, Barnes E, Andersson M, Pinedo-villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus infection in South Africa.. [DOI: 10.1101/483966] [Reference Citation Analysis]
30 Liu DX, Li PP, Guo JP, Li LL, Guo B, Jiao HB, Wu JH, Chen JM. Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy. Oncol Lett 2019;17:323-31. [PMID: 30655770 DOI: 10.3892/ol.2018.9584] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
31 Alacam S, Karabulut N, Yolcu A, Onel M, Atasoy A, Kaymakoglu S, Agacfidan A. Evaluation of drug resistance mutations in patients with chronic hepatitis B. Folia Microbiol (Praha) 2019;64:237-43. [PMID: 30259350 DOI: 10.1007/s12223-018-0650-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother 2018;62:e01064-18. [PMID: 30038044 DOI: 10.1128/AAC.01064-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
33 Mokaya J, McNaughton AL, Hadley MJ, Beloukas A, Geretti AM, Goedhals D, Matthews PC. A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action. PLoS Negl Trop Dis 2018;12:e0006629. [PMID: 30080852 DOI: 10.1371/journal.pntd.0006629] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
34 Chen BF. Hepatitis B virus pre-S/S variants in liver diseases. World J Gastroenterol 2018; 24(14): 1507-1520 [PMID: 29662289 DOI: 10.3748/wjg.v24.i14.1507] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
35 Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. Antiviral Res. 2018;154:26-34. [PMID: 29630974 DOI: 10.1016/j.antiviral.2018.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
36 Zhou Y, Xia L, Lin J, Wang H, Oyang L, Tan S, Tian Y, Su M, Wang H, Cao D, Liao Q. Exosomes in Nasopharyngeal Carcinoma. J Cancer 2018;9:767-77. [PMID: 29581754 DOI: 10.7150/jca.22505] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
37 Mokaya J, Mcnaughton AL, Hadley MJ, Beloukas A, Geretti A, Goedhals D, Matthews PC. A systematic review of Hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action.. [DOI: 10.1101/258350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
38 Gümürdülü Y, Tokmak S, Karaoğullarından Ü, Taş DA, Kara İO, Güzel AB, Khatib G. Minimal Risk of HBV Reactivation in Resolved HBV-Infected Patients During Immunosuppressive Therapy. SSRN Journal. [DOI: 10.2139/ssrn.3215516] [Reference Citation Analysis]
39 Kim DY, Lee HW, Song JE, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. J Med Virol 2018;90:497-502. [PMID: 29077211 DOI: 10.1002/jmv.24986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
40 . Entecavir/tenofovir. Reactions Weekly 2017;1664:127-127. [DOI: 10.1007/s40278-017-34406-5] [Reference Citation Analysis]
41 Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H, Li T. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 2017;9:E199. [PMID: 28749433 DOI: 10.3390/v9080199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
43 [DOI: 10.1101/19009563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Reference Citation Analysis]